News
EQS-News: Formycon lädt zur Telefonkonferenz zu den Ergebnissen des ersten Halbjahres 2026 ein und gibt Teilnahme an internationalen Investorenkonferenzen bekannt
EQS-News: Formycon lädt zur Telefonkonferenz zu den Ergebnissen des ersten Halbjahres 2026 ein und gibt Teilnahme an internationalen Investorenkonferenzen bekannt
Syndax Pharmaceuticals Q2 Earnings Call Highlights
Key Points
- Interested in Syndax Pharmaceuticals, Inc.? Here are five stocks we like better.
- Syndax’s Q2 revenue rose 92% year over year to $72.8 million, driven by Revuforj revenue of $54.7
LeMaitre Vascular Q2 Earnings Call Highlights
Key Points
- Interested in LeMaitre Vascular, Inc.? Here are five stocks we like better.
- Strong quarterly performance: LeMaitre Vascular delivered 10% organic revenue growth, record operating
Cumberland Pharmaceuticals Q2 Earnings Call Highlights
Key Points
- Interested in Cumberland Pharmaceuticals Inc.? Here are five stocks we like better.
- Cumberland completed the sale of its branded U.S. commercial portfolio to Apotex for $100 million
HealthStream Q2 Earnings Call Highlights
Key Points
- Interested in HealthStream, Inc.? Here are five stocks we like better.
- HealthStream reported record Q2 results: Revenue rose 12.5% year over year to $83.7 million, while adjusted
Compugen Q2 Earnings Call Highlights
Key Points
- Interested in Compugen Ltd.? Here are five stocks we like better.
- COM701’s MAIA-ovarian trial continues enrolling, with an interim analysis including median progression-free survival
AEVIS VICTORIA SA (AEVS.SW) – MRH Switzerland AG setzt Wachstumskurs fort und übertrifft im ersten Halbjahr 2026 den Schweizer Hotelmarkt
AEVIS VICTORIA SA (AEVS.SW) – MRH Switzerland AG setzt Wachstumskurs fort und übertrifft im ersten Halbjahr 2026 den Schweizer Hotelmarkt
Valneva Aktie: VLA15 erreicht 73,2% Wirksamkeit
Die Talsohle scheint vorerst erreicht. Nach einem Sturz auf das Jahrestief bei 2,03 Euro…
Der Beitrag Valneva Aktie: VLA15 erreicht 73,2% Wirksamkeit erschien zuerst auf kapitalmarktexperten.de.
Que
Roblox Q2 Earnings Call Highlights
Key Points
- Interested in Roblox Corporation? Here are five stocks we like better.
- Roblox’s Q2 revenue grew 36% to $1.5 billion, while bookings rose 8% to $1.6 billion, near the low end of
DT Midstream Q2 Earnings Call Highlights
DT Midstream (NYSE:DTM) said it reached final investment decisions on approximately $300 million of new organic growth projects
CareDx Q2 Earnings Call Highlights
Key Points
- Interested in CareDx, Inc.? Here are five stocks we like better.
- CareDx’s second-quarter revenue rose 52% to $132 million, driven by a 61% increase in testing-services revenue and a
Vericel Q2 Earnings Call Highlights
Key Points
- Interested in Vericel Corporation? Here are five stocks we like better.
- Record Q2 performance: Vericel’s revenue rose 22% year over year to $77.5 million, while GAAP net income
Patterson-UTI Energy Q2 Earnings Call Highlights
Key Points
- Interested in Patterson-UTI Energy, Inc.? Here are five stocks we like better.
- Second-quarter revenue rose 10% sequentially to $1.228 billion, supported by stronger drilling
Icon Q2 Earnings Call Highlights
Key Points
- Interested in Icon Plc? Here are five stocks we like better.
- Icon’s Q2 revenue rose 1.2% year over year to $2.1 billion, while adjusted EBITDA increased to $327.2 million and adjusted
EQS-News: MEDICLIN beendet solides erstes Halbjahr 2026
EQS-News: MEDICLIN beendet solides erstes Halbjahr 2026
Robert Walters H1 Earnings Call Highlights
Robert Walters (LON:RWA) said its first-half 2026 performance was in line with expectations as the recruitment firm reduced costs, continued cash-management actions and reported improving trends in
EQS-News: Drägerwerk AG & Co. KGaA: Dräger mit starker Geschäftsentwicklung im ersten Halbjahr 2026
EQS-News: Drägerwerk AG & Co. KGaA: Dräger mit starker Geschäftsentwicklung im ersten Halbjahr 2026
Bausch Health Cos Q2 Earnings Call Highlights
Key Points
- Interested in Bausch Health Cos Inc.? Here are five stocks we like better.
- Bausch Health raised its full-year outlook after reporting strong second-quarter growth: excluding Bausch +
Viking Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Viking Therapeutics, Inc.? Here are five stocks we like better.
- Viking’s losses widened as it increased investment in its obesity pipeline: Q2 net loss reached $128.1
MannKind’s Inhaled IPF Drug Clears Phase 1b Safety Hurdle, Phase 2 Underway
Key Points
- Interested in MannKind Corporation? Here are five stocks we like better.
- MannKind’s Phase 1b trial met its short-term safety and tolerability objective in 27 IPF patients, with no
Corcept Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Corcept Therapeutics Incorporated? Here are five stocks we like better.
- Second-quarter revenue rose 32% to $256.1 million, driven by growth in the Cushing’s syndrome
Boston Scientific Q2 Earnings Call Highlights
Key Points
- Interested in Boston Scientific Corporation? Here are five stocks we like better.
- Strong Q2 results, lower outlook: Boston Scientific posted 7% organic revenue growth and adjusted EPS
AxoGen Q2 Earnings Call Highlights
Key Points
- Interested in AxoGen, Inc.? Here are five stocks we like better.
- Strong revenue growth: AxoGen’s second-quarter revenue rose 23.1% year over year to $69.7 million, driven largely by
Anika Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Anika Therapeutics Inc.? Here are five stocks we like better.
- Second-quarter performance strengthened: Revenue rose 16% year over year to $32.6 million, while gross
Meridian Q2 Earnings Call Highlights
Key Points
- Interested in Meridian Holdings Inc.? Here are five stocks we like better.
- Meridian delivered stronger financial results: Second-quarter revenue rose 16% year over year to $50.2